The research is the result of a national collaboration led by investigators from the Centre for Eye Research Australia at the University of Melbourne and University of Tasmania and the Garvan Institute of Medical Research.
Stem cell research that has unveiled a detailed genetic roadmap of glaucoma – the world’s leading cause of irreversible blindness – will help scientists develop new drugs to combat the disease by identifying potential target areas to stall or reverse vision loss.
The research, one of the largest and most detailed stem cell modelling studies reported for any disease, is published in Cell Genomics.1
According to a news release from the University of Melbourne, by comparing stem cell models of the retinal ganglion cells of people with Primary Open Angle Glaucoma to those without the disease, more than 300 novel genetic features of these cells were uncovered.
The university noted that the findings are the result of a national collaboration led by Alex Hewitt, MD, PhD, (Centre for Eye Research Australia, University of Melbourne and University of Tasmania), Alice Pébay, PhD, and Maciej Daniszewski, PhD, (University of Melbourne) and Anne Senabouth and Joseph Powell, PhD, (Garvan Institute of Medical Research).
Hewitt, head of Clinical Genetics at CERA, explained in the university news
release, the study will lead to a better understanding of the mechanisms that damage retinal ganglion cells and lead to the onset of glaucoma.
Investigators noted that this will help them develop new drugs to combat glaucoma, by identifying potential new areas to target to stall or reverse vision loss caused by the disease.
Healthy retinal ganglion cells – which transmit visual information from the eye to the brain via the optic nerve – are essential for vision. In glaucoma, the gradual damage and death of these cells leads to a progressive, irreversible decline in sight.
“Glaucoma is often an inherited condition and comparing diseased retinal ganglion cells with healthy one is an effective way to increase our understanding of the mechanisms that contribute to vision loss,’’ Hewitt. Explained.
Pébay, whose team lead the stem cell aspects of this work, added that “until recently that’s been impossible because you cannot obtain or profile retinal ganglion cells from living donors without an invasive procedure.”
The university noted that in order to clear this hurdle, the team used Nobel Prize-winning induced pluripotent stem cell (iPSC) technology to ‘reprogram’ skin cells provided by donors into a stem cells that were then turned into a retinal ganglion cell in the lab.
They then mapped the individual genetic expression of almost a quarter of a million cells to identify features that could impact on the way genes are expressed in the cell, impacting its function, and potentially contributing to vision loss.
The researchers identified 312 unique genetic features in the retinal ganglion cell models that warrant further investigation.
“The sequencing identifies which genes are turned on in a cell, their level of activation and where they are turned on and off – like a road network with traffic lights,’’ according to Powell, whose team led the analysis of world leading dataset.
Powell added that the research gives investigators a genetic roadmap of glaucoma and identifies 312 sites in the genome where these lights are blinking.
“Understanding which of these traffic lights should be turned off or on will be the next step in developing new therapies to prevent glaucoma,” Powell said.
Hewitt, an ophthalmologist, pointed out that the research provides hundreds of new targets for researchers developing new drugs to treat glaucoma which is predicted to affect more than 80 million people globally by 2040.
“Current therapies are limited to slowing vision loss by reducing pressure in the eye – but they do not work for all patients and some people continue to lose many retinal ganglion cells and vision despite having normal eye pressure,” he said. “The rich source of genetic information generated by this research is an important first step towards developing new treatments that go beyond lowering eye pressure and can reverse damage and vision loss.’’
The research was the result of an extensive national collaboration including researchers from the University of Melbourne, Centre for Eye Research Australia, Garvan Institute for Medical Research, QIMR Berghofer Medical Research Institute, St Vincent’s Institute of Medical Research, St Vincent’s Hospital, Flinders University, Lion’s Eye Institute, Macquarie University, University of Tasmania and University of New South Wales.
Alex Hewitt, MD, PhD; Alice Pébay, PhD; Maciej Daniszewski, PhD; Anne Senabouth; Joseph Powell, PhD; Retinal ganglion cell-specific genetic regulation in primary open-angle glaucoma. Cell Genomics; Published; June 8, 2022; doi: 10.1016/j.zxen2022.100142